By Evangelos Pazarentzos, Ph.D., Merce Padro, Ph.D., Joan Zape, Srijib Goswami, and Gorjan Hrustanovic
Mirati Therapeutics (NASDAQ:MRTX) is a development-stage biotechnology company focusing on the development of targeted small-molecule inhibitors for the treatment of solid and hematological cancers. As of December 2013, Mirati had 62.1M cash and is burning ~$11.2M/qtr. As of writing, Mirati is valued at $218M with shares trading at $16.35.
Mirati began trading on NASDAQ in June 2013 after its reincorporation and restructuring from Methylgene, and has since been largely out of the radar of many retail biotech investors. This likely due to Methylgene's previous clinical failures, most famously with the anti-fungal program MGCD290. Since then, Methylgene (now Mirati) has completely reshuffled and revitalized its...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|